AKESO(HK:09926) Ge Long Hui·2025-08-28 00:21Group 1 - The core announcement is that 康方生物 (Kangfang Biologics) has entered into a placement agreement with Morgan Stanley to issue 23.55 million shares at a price of HKD 149.54 per share, representing a discount of approximately 4.75% from the closing price of HKD 157.00 on August 27 [1][2] - The placement shares will account for about 2.62% of the company's existing share capital and approximately 2.56% of the enlarged share capital post-placement [1] - The estimated gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion [2] Group 2 - The net proceeds from the placement will be allocated as follows: 80% for global and China innovation R&D pipeline and infrastructure development, 10% for commercialization of existing approved products, and 10% for general corporate purposes [2]